Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV–Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial
In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kleinstein, Sarah E. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coinfected |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
JST135821223 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | JST135821223 | ||
| 003 | DE-627 | ||
| 005 | 20240105090147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240105s2018 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)JST135821223 | ||
| 035 | |a (JST)26526331 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kleinstein, Sarah E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV–Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses. | ||
| 540 | |a © The Author(s) 2018 | ||
| 650 | 4 | |a genetics | |
| 650 | 4 | |a efavirenz | |
| 650 | 4 | |a ledipasvir | |
| 650 | 4 | |a sofosbuvir | |
| 650 | 4 | |a coinfected | |
| 655 | 4 | |a research-article | |
| 700 | 1 | |a Shea, Patrick R. |e verfasserin |4 aut | |
| 700 | 1 | |a Stamm, Luisa M. |e verfasserin |4 aut | |
| 700 | 1 | |a Sulkowski, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, David B. |e verfasserin |4 aut | |
| 700 | 1 | |a Naggie, Susanna |e verfasserin |4 aut | |
| 773 | 1 | 8 | |g volume:66 |g year:2018 |g number:12 |g pages:1953-1956 |
| 856 | 4 | 0 | |u https://www.jstor.org/stable/26526331 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_JST | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2018 |e 12 |h 1953-1956 | ||